StreetInsider.com News Articles

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 29

Fri, 31 Jul 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260731/26851701.html

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 29

Fri, 31 Jul 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260731/26851701.html

Form 424B5 NORTHWEST BIOTHERAPEUTIC

Fri, 31 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260731/26851688.html

Form 424B5 NORTHWEST BIOTHERAPEUTIC

Fri, 31 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260731/26851688.html

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 17

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786466.html

Form 8-K NORTHWEST BIOTHERAPEUTIC For: Jul 17

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786466.html

NWBio updated DCVax-L trial data suggests original survival gains were underestimated

Wed, 08 Jul 2026 14:25:09 -0400

Northwest Biotherapeutics (OTCQB: NWBO) presented updated survival data from its Phase III trial of DCVax-L for glioblastoma at the 2026 Annual Meeting of the British Neuro-Oncology Society, according to a company statement.

The new analyses, conducted by independent statisticians using individual patient-level data (IPD), suggest the survival benefit previously reported from the trial was likely underestimated. The original analysis, which relied on cohort-level data, found a median survival advantage of 2.8 months for DCVax-L patients.

Using two statistical methods — propensity score matching (PSM) and inverse probability weighting (IPW) — the independent statisticians compared DCVax-L patients against controls drawn from several randomized

NWBio updated DCVax-L trial data suggests original survival gains were underestimated

Wed, 08 Jul 2026 14:25:09 -0400

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Wed, 08 Jul 2026 14:24:00 -0400

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated

BETHESDA, Md., July 8, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the Company's Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax®-L for glioblastoma (GBM) at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The updated data included results of multiple different statistical analyses conducted by independent statisticians, using individual patient-level data

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Wed, 08 Jul 2026 14:24:00 -0400

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Wed, 08 Jul 2026 14:24:00 -0400

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Wed, 08 Jul 2026 14:24:00 -0400

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated

NWBio to present DCVax-L survival data at UK neuro-oncology meeting

Thu, 02 Jul 2026 14:19:20 -0400

Northwest Biotherapeutics (OTCQB: NWBO) announced that its Chief Technical Officer, Dr. Marnix Bosch, will present survival data on its DCVax-L therapy at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS) on July 3.

The presentation, titled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses," is scheduled for 10:00 a.m. GMT and will examine the association between DCVax-L treatment and patient survival using propensity score matching methodologies.

The company said the slide deck will be posted to its website following the presentation.

DCVax-L is Northwest Biotherapeutics' lead therapy candidate for glioblastoma, an aggressive form of primary brain cancer. The company has

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Thu, 02 Jul 2026 14:17:00 -0400

BETHESDA, Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be making a scientific presentation entitled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses" at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The presentation is scheduled for Friday, July 3, at 10:00 a.m. GMT, and will address the association between DCVax-L treatment and patient survival using propensity score matching methodologies (PSM). The

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Thu, 02 Jul 2026 14:17:00 -0400

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Thu, 02 Jul 2026 14:17:00 -0400

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Thu, 02 Jul 2026 14:17:00 -0400

Form 10-Q NORTHWEST BIOTHERAPEUTIC For: Mar 31

Fri, 15 May 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260515/26506799.html

Form 10-Q NORTHWEST BIOTHERAPEUTIC For: Mar 31

Fri, 15 May 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260515/26506799.html

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities